-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Influenza viruses continue to threaten global public health security
In this study, the research team screened for this strain to neutralize cross-subtypes of H1N1 influenza viruses since 1991 (seasonal H1N1 circulating before 2009 and A H1N1 circulating since 2009) and H5N1 avian influenza viruses After the broad-spectrum neutralizing antibody 12H5, in order to explore the clinical application prospect and action mechanism of 12H5, a human-mouse chimeric antibody C12H5, a mouse-derived 12H5 antibody, was constructed, and then systematic research was carried out
(a) Hemagglutination inhibitory activity and micro-neutralizing activity of H1N1 and H5N1 influenza virus cross broad-spectrum neutralizing antibody C12H5; (b) protective effect in animals; (c) epitope structure comparison with the reported broad-spectrum antibody; ( d) H1 and H5 common epitope amino acids
Recently, the research results were published online in Nature Communications as a research paper entitled "Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses"
Paper link:National Research Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology)